These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Author: Zdziarska J, Chojnowski K, Klukowska A, Łetowska M, Mital A, Podolak-Dawidziak M, Windyga J, Zawilska K, Working Group on Hemostasis of the Polish Society of Hematologists and Transfusiologists.
    Journal: Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223.
    Abstract:
    Advances in hemophilia management in the 20th century enabled effective and early treatment of joint and other bleeds typical of this disease, also in a home setting. Prophylaxis became available as the optimal approach to prevent hemophilic arthropathy and improve patients' quality of life. To increase treatment safety, lyophilized plasma-derived factor VIII and IX concentrates were subjected to numerous procedures designed to decrease the risk of transmission of known and unknown pathogens. During the following years, recombinant factor VIII and factor IX preparations were developed to completely eliminate the risk. Recombinant factor concentrates were extensively studied in terms of their therapeutic properties, safety, and immunogenicity. This article reviews the current knowledge on efficacy and safety of recombinant factors VIII and IX.
    [Abstract] [Full Text] [Related] [New Search]